Home › Companies › Kura Oncology, Inc. › 2025-2026

Kura Oncology, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Kura Oncology, Inc.’s Form 8-K, filed June 4, 2026 (Item 5.07 on EDGAR). Page generated October 18, 2026.

  • 8Reported items
  • 202Asset managers
  • 1,831Fund votes
  • June 4, 2026Meeting date

Results at a glance

Meeting of June 4, 2026: 7 items on Kura Oncology, Inc.’s Form 8-K, filed June 4, 2026: 3 approved · 4 without a stated outcome.

Material dissent

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Kura Oncology, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Kura Oncology, Inc.

These tallies are Kura Oncology, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Kura Oncology, Inc. — official shareholder meeting results, meeting held June 4, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Diane Parks 44,060,724---- 14,620,30811,097,548 75%Not verified—
Elect Director: Mary T. Szela 38,859,502---- 19,821,53011,097,548 66%Not verified—
Elect Director: Michael J. Vasconcelles, M.D. 58,169,894---- 511,13811,097,548 99.1%Not verified—
2. Ratification of the Appointment of Independent Registered Public Accounting Firm 69,385,497140,763252,320 ---- 99.7%Approved—
3. Advisory Vote on Executive Compensation 48,783,8341,141,8548,755,344 --11,097,548 98%Not verified—
5. Approval of our Amended 2014 Plan 48,402,82010,099,296178,916 --11,097,548 83%Approved—
6. Approval of our Amended ESPP 58,306,174213,434161,424 --11,097,548 99.6%Approved—

Source: Kura Oncology, Inc., Form 8-K, filed with the SEC on June 4, 2026 — read the filing on EDGAR.

How asset managers voted at the Kura Oncology, Inc. 2025-2026 meeting

Each item below shows how the 202 asset managers that disclosed a Kura Oncology, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Kura Oncology, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: Diane Parks

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

75% Majority: yes · of votes cast

FOR 75%WITHHELD
FOR: 44,060,724WITHHELD: 14,620,308
Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: Election of three Class III directors for three-year terms: Diane Parks

Kura Oncology, Inc.’s own tally for this item (“Elect Director: Diane Parks”): 44,060,724 for, 14,620,308 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 75% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 10,505,118 for, 5,473,587 withheld, 33 abstained.

FORWITHHOLD
FOR: 10,505,118ABSTAIN: 33WITHHOLD: 5,473,587
Largest asset managers voting on “Election of three Class III directors for three-year terms: Diane Parks” at Kura Oncology, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard4,962,2530 3310,829For
State Street2,0700 02,761,993Withhold
BlackRock2,312,2100 00For
Fidelity2,128,2060 00For
Charles Schwab00 0690,994Withhold
Dimensional00 0474,849Withhold
American Century00 0412,978Withhold
Nationwide22,0250 0226,788Mixed
Columbia Threadneedle202,4500 00For
Equitable117,6550 056,700Mixed
TIAA148,0830 00For
QUANTITATIVE MASTER SERIES LLC137,0180 00For
GuideStone00 0135,479Withhold
Invesco132,7140 00For
MASTER INVESTMENT PORTFOLIO83,4220 00For
ETFis Series Trust I00 082,610Withhold
Goldman Sachs75,3980 00For
ProShares00 075,304Withhold
ALPS ETF Trust00 071,906Withhold
Northern Trust00 060,062Withhold
Lincoln Financial00 057,164Withhold
Harbor ETF Trust55,5300 00For
AIG/SunAmerica00 040,938Withhold
Direxion Shares ETF Trust00 038,265Withhold
Global X00 037,586Withhold

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

2. Elect Director: Mary T. Szela

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

66% Majority: yes · of votes cast

FOR 66%WITHHELD
FOR: 38,859,502WITHHELD: 19,821,530
Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: Election of three Class III directors for three-year terms: Mary T. Szela

Kura Oncology, Inc.’s own tally for this item (“Elect Director: Mary T. Szela”): 38,859,502 for, 19,821,530 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 66% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 8,220,993 for, 7,757,698 withheld, 46 abstained.

FORWITHHOLD
FOR: 8,220,993ABSTAIN: 46WITHHOLD: 7,757,698
Largest asset managers voting on “Election of three Class III directors for three-year terms: Mary T. Szela” at Kura Oncology, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard4,962,2400 4610,829For
State Street2,756,4160 07,647For
BlackRock00 02,312,210Withhold
Fidelity00 02,128,206Withhold
Charles Schwab00 0690,994Withhold
Dimensional00 0474,849Withhold
American Century00 0412,978Withhold
Nationwide00 0248,813Withhold
Columbia Threadneedle00 0202,450Withhold
Equitable00 0174,355Withhold
TIAA148,0830 00For
QUANTITATIVE MASTER SERIES LLC00 0137,018Withhold
GuideStone00 0135,479Withhold
Invesco132,7140 00For
MASTER INVESTMENT PORTFOLIO00 083,422Withhold
ETFis Series Trust I00 082,610Withhold
Goldman Sachs75,3980 00For
ProShares00 075,304Withhold
ALPS ETF Trust00 071,906Withhold
Northern Trust00 060,062Withhold
Lincoln Financial55,3990 01,765For
Harbor ETF Trust55,5300 00For
AIG/SunAmerica00 040,938Withhold
Direxion Shares ETF Trust00 038,265Withhold
Global X00 037,586Withhold

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

3. Elect Director: Michael J. Vasconcelles, M.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%
FOR: 58,169,894WITHHELD: 511,138
Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: Election of three Class III directors for three-year terms: Michael J. Vasconcelles, M.D.

Kura Oncology, Inc.’s own tally for this item (“Elect Director: Michael J. Vasconcelles, M.D.”): 58,169,894 for, 511,138 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.1% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 15,907,191 for, 71,545 withheld, 1 abstained.

FOR
FOR: 15,907,191ABSTAIN: 1WITHHOLD: 71,545
Largest asset managers voting on “Election of three Class III directors for three-year terms: Michael J. Vasconcelles, M.D.” at Kura Oncology, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard4,973,1140 10For
State Street2,764,0630 00For
BlackRock2,312,2100 00For
Fidelity2,128,2060 00For
Charles Schwab690,9940 00For
Dimensional474,8490 00For
American Century412,9780 00For
Nationwide248,8130 00For
Columbia Threadneedle202,4500 00For
Equitable117,6550 056,700Mixed
TIAA148,0830 00For
QUANTITATIVE MASTER SERIES LLC137,0180 00For
GuideStone135,4790 00For
Invesco132,7140 00For
MASTER INVESTMENT PORTFOLIO83,4220 00For
ETFis Series Trust I82,6100 00For
Goldman Sachs75,3980 00For
ProShares75,3040 00For
ALPS ETF Trust71,9060 00For
Northern Trust60,0620 00For
Lincoln Financial57,1640 00For
Harbor ETF Trust55,5300 00For
AIG/SunAmerica40,9380 00For
Direxion Shares ETF Trust38,2650 00For
Global X37,5860 00For

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

4. APPROVAL OF AN AMENDMENT TO OUR 2015 EMPLOYEE STOCK PURCHASE PLAN.

No official matchCOMPENSATION

99.8% of fund votes cast · no official result

FOR
Details: votes by 57 asset managers

The 57 asset managers below reported 15,948,292 for, 30,445 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 15,948,292AGAINST: 30,445
Largest asset managers voting on “APPROVAL OF AN AMENDMENT TO OUR 2015 EMPLOYEE STOCK PURCHASE PLAN.” at Kura Oncology, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard4,973,1150 00For
State Street2,764,0630 00For
BlackRock2,312,2100 00For
Fidelity2,128,2060 00For
Charles Schwab690,9940 00For
Dimensional474,8490 00For
American Century412,9780 00For
Nationwide248,8130 00For
Columbia Threadneedle202,4500 00For
Equitable174,3550 00For
TIAA148,0830 00For
QUANTITATIVE MASTER SERIES LLC137,0180 00For
GuideStone135,4790 00For
Invesco132,7140 00For
MASTER INVESTMENT PORTFOLIO83,4220 00For
ETFis Series Trust I82,6100 00For
Goldman Sachs75,3980 00For
ProShares75,3040 00For
ALPS ETF Trust71,9060 00For
Northern Trust60,0620 00For
Lincoln Financial57,1640 00For
Harbor ETF Trust55,5300 00For
AIG/SunAmerica40,9380 00For
Direxion Shares ETF Trust38,2650 00For
Global X37,5860 00For

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

5. 5. Approval of our Amended 2014 Plan

Official resultCOMPENSATIONReported outcome: Approved

83% Approved · of votes cast

FOR 83%AGAINST
FOR: 48,402,820AGAINST: 10,099,296
Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: APPROVAL OF AN AMENDMENT TO OUR AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN.

Kura Oncology, Inc.’s own tally for this item (“5. Approval of our Amended 2014 Plan”): 48,402,820 for, 10,099,296 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(5) approved our Amended 2014 Plan”
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 13,196,998 for, 2,761,951 against, 19,788 abstained.

FORAGAINST
FOR: 13,196,998AGAINST: 2,761,951ABSTAIN: 19,788
Largest asset managers voting on “APPROVAL OF AN AMENDMENT TO OUR AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN.” at Kura Oncology, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard4,965,7767,339 00For
State Street2,757,1896,874 00For
BlackRock2,312,2100 00For
Fidelity1,819,898308,308 00Mixed
Charles Schwab690,9940 00For
Dimensional0474,849 00Against
American Century0412,978 00Against
Nationwide26,260222,553 00Mixed
Columbia Threadneedle0202,450 00Against
Equitable117,65556,700 00Mixed
TIAA0148,083 00Against
QUANTITATIVE MASTER SERIES LLC137,0180 00For
GuideStone0135,479 00Against
Invesco0132,714 00Against
MASTER INVESTMENT PORTFOLIO83,4220 00For
ETFis Series Trust I082,610 00Against
Goldman Sachs075,398 00Against
ProShares075,304 00Against
ALPS ETF Trust071,906 00Against
Northern Trust060,062 00Against
Lincoln Financial55,3991,765 00For
Harbor ETF Trust55,5300 00For
AIG/SunAmerica040,938 00Against
Direxion Shares ETF Trust038,265 00Against
Global X37,5860 00For

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

6. 3. Advisory Vote on Executive Compensation

Outcome not verifiedFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Not verified

Combines 9 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 48,783,834AGAINST: 1,141,854
Details: description as filed, official tally, votes by 202 asset managers

Description as filed by funds: Approval, on an advisory basis, of the compensation of our named executive officers ("Say-on-Pay"), as disclosed in the proxy statement.

Kura Oncology, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 48,783,834 for, 1,141,854 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 57 asset managers voting on “Approval, on an advisory basis, of the compensation of our named executive officers ("Say-on-Pay"), as disclos” at Kura Oncology, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard4,973,0911 220For
State Street2,762,9591,104 00For
BlackRock2,312,2100 00For
Fidelity2,128,2060 00For
Charles Schwab690,9940 00For
Dimensional474,8490 00For
American Century0412,978 00Against
Nationwide248,8130 00For
Columbia Threadneedle202,4500 00For
Equitable174,3550 00For
TIAA148,0830 00For
QUANTITATIVE MASTER SERIES LLC137,0180 00For
GuideStone135,4790 00For
Invesco132,7140 00For
MASTER INVESTMENT PORTFOLIO83,4220 00For
ETFis Series Trust I82,6100 00For
Goldman Sachs75,3980 00For
ProShares75,3040 00For
ALPS ETF Trust71,9060 00For
Northern Trust60,0620 00For
Lincoln Financial57,1640 00For
Harbor ETF Trust55,5300 00For
AIG/SunAmerica40,9380 00For
Direxion Shares ETF Trust38,2650 00For
Global X37,5860 00For

Fund voting reports, all 57 managers: 15,549,786 for, 414,083 against, 14,867 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 165 asset managers voting on “Approval, on an advisory basis, of the compensation of our named executive officers ("Say-on-Pay"), as disclos” at Kura Oncology, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BVF INC/IL00 8,445,7690Abstain
MONTANOVA CAPITAL, LLC6,267,3940 00For
State Street4,270,53414,848 00For
BlackRock3,989,71650,658 00For
GEODE CAPITAL MANAGEMENT, LLC2,034,2760 00For
Deep Track Capital, LP1,885,8900 00For
NAN FUNG TRINITY (HK) Ltd1,064,8800 00For
AQR956,3090 00For
1492 Capital Management LLC927,6250 00For
Logos Global Management LP751,3310 00For
Charles Schwab691,2190 00For
Vanguard676,5490 00For
Northern Trust600,98513,736 00For
Renaissance549,8850 00For
Fisher Asset Management, LLC538,7150 00For
Prosight Management, LP467,3790 00For
Invesco452,5890 00For
American Century0442,925 00Against
ARMISTICE CAPITAL, LLC433,1930 00For
GREAT LAKES ADVISORS, LLC339,2070 00For
SECTOR GAMMA AS324,5030 00For
Fidelity319,6280 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC282,0450 00For
Connor, Clark & Lunn Investment Management Ltd.247,3560 00For
DAFNA Capital Management LLC235,8680 00For

Institutional-manager reports, all 165 managers: 31,085,608 for, 868,754 against, 8,466,774 abstained, 8,445 not voted, 14,258 1 year, 174 unknown. Showing the 25 largest; see all in the interactive database.

7. INDICATION, ON AN ADVISORY BASIS, OF THE PREFERRED FREQUENCY OF HOLDING FUTURE SAY-ON-PAY VOTES ON EXECUTIVE…

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

100% Fund and manager reports combined; may count the same shares twice · no official result

ABSTAIN1 YEAR
Details: description as filed, votes by 197 asset managers

Description as filed by funds: INDICATION, ON AN ADVISORY BASIS, OF THE PREFERRED FREQUENCY OF HOLDING FUTURE SAY-ON-PAY VOTES ON EXECUTIVE COMPENSATION.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 57 asset managers voting on “INDICATION, ON AN ADVISORY BASIS, OF THE PREFERRED FREQUENCY OF HOLDING FUTURE SAY-ON-PAY VOTES ON EXECUTIVE C” at Kura Oncology, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard00 220Abstain
State Street00 00--
BlackRock00 00--
Fidelity00 00--
Charles Schwab00 00--
Dimensional00 00--
American Century00 00--
Nationwide00 00--
Columbia Threadneedle00 00--
Equitable00 00--
TIAA00 00--
QUANTITATIVE MASTER SERIES LLC00 00--
GuideStone00 00--
Invesco00 00--
MASTER INVESTMENT PORTFOLIO00 00--
ETFis Series Trust I00 00--
Goldman Sachs00 00--
ProShares00 00--
ALPS ETF Trust00 00--
Northern Trust00 00--
Lincoln Financial00 00--
Harbor ETF Trust00 00--
AIG/SunAmerica00 00--
Direxion Shares ETF Trust00 00--
Global X00 00--

Fund voting reports, all 57 managers: 20,921 for, 14,867 abstained, 15,429,188 1 year, 513,641 3 year, 120 unknown. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 160 asset managers voting on “INDICATION, ON AN ADVISORY BASIS, OF THE PREFERRED FREQUENCY OF HOLDING FUTURE SAY-ON-PAY VOTES ON EXECUTIVE C” at Kura Oncology, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BVF INC/IL00 8,445,7690Abstain
MONTANOVA CAPITAL, LLC00 00--
State Street00 00--
BlackRock00 00--
GEODE CAPITAL MANAGEMENT, LLC00 00--
Deep Track Capital, LP00 00--
NAN FUNG TRINITY (HK) Ltd00 00--
AQR00 00--
Logos Global Management LP00 00--
Charles Schwab00 00--
Vanguard00 00--
Northern Trust00 00--
Renaissance00 00--
Fisher Asset Management, LLC00 00--
1492 Capital Management LLC00 00--
Prosight Management, LP00 00--
Invesco00 00--
American Century00 00--
ARMISTICE CAPITAL, LLC00 00--
GREAT LAKES ADVISORS, LLC00 00--
Fidelity00 00--
PARAMETRIC PORTFOLIO ASSOCIATES LLC00 00--
Connor, Clark & Lunn Investment Management Ltd.00 00--
DAFNA Capital Management LLC00 00--
ACADIAN ASSET MANAGEMENT LLC00 00--

Institutional-manager reports, all 160 managers: 14,258 for, 8,445,769 abstained, 8,445 not voted, 31,031,190 1 year, 156,391 3 year. Showing the 25 largest; see all in the interactive database.

8. 2. Ratification of the Appointment of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

99.7% Approved · of votes cast

FOR 99.7%
FOR: 69,385,497AGAINST: 140,763
Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2026.

Kura Oncology, Inc.’s own tally for this item (“2. Ratification of the Appointment of Independent Registered Public Accounting Firm”): 69,385,497 for, 140,763 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(2) ratified the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 15,963,782 for, 110 against, 14,845 abstained.

FOR
FOR: 15,963,782AGAINST: 110ABSTAIN: 14,845
Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ” at Kura Oncology, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard4,973,1150 00For
State Street2,763,953110 00For
BlackRock2,312,2100 00For
Fidelity2,128,2060 00For
Charles Schwab690,9940 00For
Dimensional474,8490 00For
American Century412,9780 00For
Nationwide248,8130 00For
Columbia Threadneedle202,4500 00For
Equitable174,3550 00For
TIAA148,0830 00For
QUANTITATIVE MASTER SERIES LLC137,0180 00For
GuideStone135,4790 00For
Invesco132,7140 00For
MASTER INVESTMENT PORTFOLIO83,4220 00For
ETFis Series Trust I82,6100 00For
Goldman Sachs75,3980 00For
ProShares75,3040 00For
ALPS ETF Trust71,9060 00For
Northern Trust60,0620 00For
Lincoln Financial57,1640 00For
Harbor ETF Trust55,5300 00For
AIG/SunAmerica40,9380 00For
Direxion Shares ETF Trust38,2650 00For
Global X37,5860 00For

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

Largest Kura Oncology, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 88,774,365 shares outstanding at the time of that meeting.

Fund voting reports: top Kura Oncology, Inc. shareholders by shares voted on “Approval, on an advisory basis, of the compensation of our named executive officers…”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 5.60%
2State Street 3.11%
3BlackRock 2.60%
4Fidelity 2.40%
5Charles Schwab 0.78%
6Dimensional 0.53%
7American Century 0.47%
8Nationwide 0.28%
9Columbia Threadneedle 0.23%
10Equitable 0.20%
Institutional-manager reports: top Kura Oncology, Inc. shareholders by shares voted on “Approval, on an advisory basis, of the compensation of our named executive officers…”, 2025-2026
#Asset manager % of shares outstanding
1BVF INC/IL 9.51%
2MONTANOVA CAPITAL, LLC 7.06%
3State Street 4.83%
4BlackRock 4.55%
5GEODE CAPITAL MANAGEMENT, LLC 2.29%
6Deep Track Capital, LP 2.12%
7NAN FUNG TRINITY (HK) Ltd 1.20%
8AQR 1.08%
91492 Capital Management LLC 1.04%
10Logos Global Management LP 0.85%

Reported Kura Oncology, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Kura Oncology, Inc. holdings and ownership disclosed for the 2025-2026 proxy season
Holder % outstanding Disclosure
BlackRock 10.86% 13F
BVF Partners L.P. 9.84% DEF14A
Montanova Capital, LLC 9.66% 13G
Suvretta Capital Management, LLC 8.52% DEF14A
Vanguard Group 6.20% 13F
Armistice Capital 5.56% DEF14A
STATE STREET CORPORATION 5.55% 13G
Troy E. Wilson, Ph.D., J.D. 4.13% DEF14A
Geode Capital 2.29% 13F
Renaissance Technologies 1.78% 13F

Percentages above are of 88,774,365 shares outstanding, as reported by Kura Oncology, Inc. on its Form 10-Q dated May 8, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Kura Oncology, Inc.’s 10-Q dated May 8, 2026. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At Kura Oncology, Inc.'s shareholder meeting held June 4, 2026, in the 2025-2026 proxy season, 202 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,831 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval, on an advisory basis, of the compensation of our named executive officers… — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Kura Oncology, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2026.

Kura Oncology, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.